近期，伴随政策持续赋能与国际化进程加速，我国创新药产业迎来高质量发展新阶段。恒生创新药ETF （520500）作为聚焦港股创新药龙头企业的投资工具之一，正获得市场广泛关注。行业基本面向好，叠 加流动性预期改善，创新药板块配置价值或凸显。 政策来源：2025/9/12，国家药监局-《关于优化创新药临床试验审评审批有关事项的公告》 风险提示：基金有风险，投资需谨慎。如需购买相关基金产品，请您关注投资者适当性管理相关规定， 提前做好风险测评，并根据您自身的风险承受能力购买与之相匹配的风险等级的基金产品。基金的过往 业绩并不预示其未来表现，基金管理人管理的其他基金的业绩并不构成基金业绩表现的保证。基金投资 需注意投资风险，请仔细阅读基金合同、基金招募说明书和产品资料概要等法律文件，了解基金的具体 情况。本基金可投资于境外证券市场，还将面临汇率风险、境外证券市场风险等特殊投资风险。指数由 恒生指数公司编制并发布，其所有权归属恒生指数公司。指数由恒生指数有限公司（"恒生"）编制和计 算，其所有权归属恒生。恒生将采取一切必要措施以确保指数的准确性，但不对此作任何保证，亦不因 指数的任何错误对任何人负责。 MACD金叉信号形 ...

Core Insights - The Chinese innovative pharmaceutical industry is at a historic juncture, with significant overseas licensing deals and challenges arising from potential U.S. regulatory scrutiny [2][3]. Group 1: Market Performance - In 2024, the Chinese innovative drug sector achieved 94 overseas licensing transactions totaling $51.9 billion [5]. - By mid-2025, the momentum continued with 72 transactions exceeding $60 billion, surpassing the previous year's total of $8.1 billion [6]. - The secondary market for biopharmaceuticals has shown signs of recovery, with companies like BeiGene reaching a market cap of over 500 billion yuan [7]. Group 2: Regulatory Challenges - The Trump administration is considering mandatory reviews by the Committee on Foreign Investment in the United States (CFIUS) for transactions involving U.S. pharmaceutical companies acquiring rights to Chinese drugs [8]. - If implemented, this could hinder the supply channels for Chinese experimental therapies to the U.S. market, impacting both U.S. and Chinese pharmaceutical companies [8]. Group 3: Financial Dynamics - Despite high transaction volumes, upfront payments for Chinese pharmaceutical deals remain significantly lower than those in the U.S., with only $2.9 billion in upfront payments out of $60.8 billion in total transactions [10]. - The disparity indicates a persistent reliance on "cost-performance" perceptions, leading to a notable valuation gap compared to international markets [10]. Group 4: Investment Trends - The domestic biopharmaceutical investment landscape is still in a downturn, with 371 financing events totaling approximately 20 billion yuan, reflecting a year-on-year decline of 31.2% [13]. - However, the industry is transitioning from a "burning cash" phase to demonstrating healthier self-sustaining capabilities, as evidenced by companies like BeiGene achieving profitability for the first time [16]. Group 5: Innovation and Collaboration - The integration of artificial intelligence in drug development is enhancing global competitiveness by reducing costs and shortening timelines [17]. - The NewCo model, which involves local investment institutions leading new company formations, is gaining traction, providing a flexible exit mechanism for early-stage innovations [21][20].

Core Insights - The innovation drug industry in China is experiencing significant advancements in product research and development, with companies actively discussing their progress and strategies during the recent performance briefing session [1][2][3]. Group 1: Product Innovation and R&D Progress - Companies like Fudan Zhangjiang and Olin Bio are making notable advancements in their product pipelines, focusing on photodynamic therapy and vaccines for "super bacteria" [1][2]. - Fudan Zhangjiang is developing several drugs targeting conditions such as severe acne and bladder cancer, with ongoing clinical studies [2]. - Olin Bio is researching multiple vaccines for "super bacteria," aiming to initiate clinical trials for flu vaccines by mid-2025 [2]. Group 2: Business Expansion and Market Strategy - Companies are planning to expand their production capacity to support product commercialization, with Baiyao Tai focusing on launching several products that have completed Phase III clinical trials [3][4]. - Shian Bio is set to contribute significant revenue from its various vaccine products, including those for swine fever and other diseases [4]. Group 3: Internationalization and Market Entry - The trend of "going global" is a major focus for the domestic biopharmaceutical industry, with companies exploring diverse international pathways [5]. - Yuantong Bio is awaiting FDA approval for its naloxone nasal spray, marking a step towards international market entry [5]. - Aidi Pharmaceutical has received regulatory approval for its HIV treatment in Zanzibar, highlighting its international expansion efforts [6]. - Companies like Ailis and Haichuang Pharmaceutical are actively pursuing overseas partnerships and clinical trials to enhance their global presence [6][7].

Group 1 - The AiTech Forum focused on providing a clear pathway for Chinese pharmaceutical companies to expand internationally, with insights from global institutions and industry representatives [1][2] - Ireland is positioned as a regulatory hub for the EU, offering compliance guidance and local infrastructure support to assist Chinese pharmaceutical companies in entering the European market [1] - The International Drug Information Association (DIA) aims to facilitate deep cooperation among global regulatory bodies and support Chinese innovative drug companies in establishing a "dual circulation" model for international market access [1][2] Group 2 - The "three-tier service system" for technology transfer includes demand-side connections with hospitals and large enterprises, supply-side integration of university innovations, and service-side support for IP rights and global resource networks [2] - Local innovative pharmaceutical companies shared their strategies for international expansion, emphasizing the importance of product strength and market timing [2] - Companies are prioritizing emerging markets for vaccine registration and sales, while also developing new vaccine technologies [2] Group 3 - China is becoming a significant source of innovative drugs for multinational pharmaceutical companies, with advantages in regulatory alignment, cost efficiency, and innovation capabilities [3] - A strategic cooperation signing ceremony was held to create a platform for ongoing collaboration among government, enterprises, international institutions, and financial capital [3] - The goal is to accelerate the globalization of China's innovative drug industry and inject new momentum into the high-quality development of the biopharmaceutical sector [3]

Core Insights - The domestic innovative pharmaceutical companies are experiencing a surge in overseas expansion, with BD transaction amounts reaching new highs, making outbound licensing a key pathway for China's pharmaceutical industry to engage in global competition and achieve industrial upgrades [1] Group 1: Market Trends - In the first half of 2025, the total transaction value of China's innovative drugs reached $63.55 billion, surpassing the total for the entire year of 2024 and accounting for approximately 40% of the global license-out transaction total [1] - Leading innovative drug companies have completed multiple product lines or international layouts, maintaining stable and rapid revenue growth, with some companies successfully turning losses into profits [1] Group 2: Company Performance - BeiGene achieved a net profit of 450 million yuan in H1, marking its first profitable period [1] - Innovent Biologics reported a net profit of 834 million yuan, continuing its profitability trend [1] Group 3: Market Reactions - In the secondary market, ETFs focused on innovative drugs and CXO sectors experienced declines, with the Hang Seng Medical ETF (159892) and the Hong Kong Stock Connect Medical ETF (520510) both dropping over 1% [1] - Innovent Biologics saw a decline of over 6%, with other companies like Legend Biotech, InnoCare Pharma, JD Health, and Alibaba Health also leading the downturn [1] - Despite the market declines, the Hang Seng Medical ETF has seen three consecutive days of capital inflow [1]

Core Viewpoint - The Hong Kong innovative drug ETF (159570) has seen significant growth, with a recent increase of nearly 2% and a rapid transaction volume exceeding 1.5 billion yuan in just three days, indicating strong market interest and liquidity in the sector [1][3]. Market Performance - As of September 15, the latest scale of the Hong Kong innovative drug ETF (159570) surpassed 22.5 billion yuan, leading in both scale and liquidity among its peers [1]. - The index components of the ETF showed mixed performance, with notable gains from companies like药捷安康 (over 50% increase) and 同源康医药 (over 14% increase), while others like 诺诚健华 and 百济神州 experienced declines [3]. Industry Trends - The continuous growth of Chinese innovative drugs in international markets is driven by collaborations with multinational corporations (MNCs), which benefit from China's efficient and cost-effective R&D pipelines [4]. - The innovative drug sector is currently in a transitional phase, with increased focus on international expansion and the realization of value through milestones and competitive advantages [4]. Clinical Developments - At the World Lung Cancer Conference (WCLC), several clinical data updates for Chinese innovative drugs were presented, particularly highlighting the promising results of ADC therapies [5]. - The release of clinical data for drugs like HLX43 and Eiza-bren indicates significant advancements in treatment efficacy for specific cancer patient populations [5]. Policy Environment - The National Healthcare Security Administration (NHSA) is set to release the 2025 medical insurance drug list, which will significantly impact companies involved in negotiations for drug inclusion [5]. - The approval of orphan drugs and imported PD-1/L-1 drugs for the insurance directory reflects a supportive policy environment for innovative drug development [5]. Financial Outlook - The anticipated easing of monetary policy by the Federal Reserve is expected to improve liquidity in the market, which could positively influence the financing environment for innovative drug companies [6]. - The A+H share innovative drug index has shown substantial growth, suggesting a favorable investment climate and potential for increased capital inflow [6]. Investment Recommendations - The Hong Kong innovative drug ETF (159570) is highlighted as a key investment vehicle, with a significant increase of over 109% in the past year, outperforming other indices [7][8]. - Investors are encouraged to focus on the underlying assets and the potential for T+0 trading, which enhances liquidity and trading flexibility [9].

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of September 15, 2025 [1] Core Insights - The trend of Chinese innovative drugs going overseas continues, with a focus on selective opportunities. The report highlights that the global pharmaceutical transaction volume reached 456 deals in the first half of 2025, a 32% year-on-year increase, with upfront payments totaling $11.8 billion, a 136% surge, and total transaction value hitting $130.4 billion, up 58% year-on-year [2] - The report emphasizes the promising clinical data from Chinese innovative drugs presented at the World Lung Cancer Conference, particularly in the ADC (Antibody-Drug Conjugate) field, showcasing significant efficacy advantages [3] - The report discusses the potential of small nucleic acid drugs and innovative delivery systems, indicating new market opportunities arising from strategic collaborations between Chinese companies and multinational corporations [4] - The CXO (Contract Research Organization) sector is expected to gradually recover, with a notable increase in orders anticipated in the third quarter of 2025, driven by improved innovation environments and funding from license-out transactions [5] - The 2025 medical insurance negotiation and commercial insurance innovative drug directory work has commenced, with a focus on orphan drugs and breakthrough treatment varieties [6] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry underperformed the CSI 300 index by 1.75% in the past week, with a recent one-month increase of 3.32%, lagging behind the CSI 300 by 5.81% [22][26] - The medical device sector showed the highest weekly increase of 2.23%, while the chemical pharmaceutical sector experienced a decline of 2.57% [31] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index's current PE (TTM) stands at 40.60, above the five-year historical average of 31.60 [46] - The report notes that the pharmaceutical sector has shown a 15.06% increase over the past three months, outperforming the CSI 300 by 16.11% [43] 3. Recent Research Achievements - The report outlines recent research achievements by the Huaxin pharmaceutical team, including various in-depth and commentary reports on innovative drug developments and market trends [50] 4. Recent Industry Policies and News - The report details recent policy updates from the National Healthcare Security Administration regarding the 2025 drug directory adjustments and the approval of new drug applications [52][55]

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Viewpoints - The report focuses on investment opportunities in the dual-antibody treatments in the autoimmune sector, highlighting the unmet needs in existing therapies and the potential for blockbuster drugs [5][15] - The report emphasizes the long-term trends in innovative drugs, the recovery of the CRO industry, and the potential for growth in various sub-sectors of the pharmaceutical industry [8][22][28] Summary by Relevant Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 9157.77, with a 52-week high of 9323.49 and a low of 6070.89 [2] Recent Market Performance - During the week of September 8 to September 12, 2025, the A-share pharmaceutical and biotechnology sector fell by 0.36%, underperforming the CSI 300 index by 1.75 percentage points and the ChiNext index by 2.47 percentage points [7][19][36] Investment Recommendations 1. **Innovative Drugs**: The report suggests that domestic innovative drugs are poised for global competition, with significant potential for growth in the oncology and respiratory sectors. Beneficiaries include companies like Innovent Biologics and Junshi Biosciences [8][22] 2. **CRO Sector**: The report indicates that the CRO industry is expected to see a recovery in profitability due to stable competition and increasing demand from innovative drug development [22][24] 3. **Biological Products**: Focus on core product volume opportunities and potential valuation re-evaluations based on product data or business development expectations. Key companies include TianTan Bio and Anke Bio [9][28] 4. **Medical Devices**: The report anticipates a turning point in the medical device sector due to improved procurement processes and funding availability [29] 5. **Traditional Chinese Medicine**: The report highlights opportunities in innovative research and policies benefiting traditional Chinese medicine companies [32][34] Market Trends - The report notes that the overall valuation of the pharmaceutical sector (TTM) is 31.72, with a relative valuation premium of 136.86% over the CSI 300 index, indicating a slight decrease from the previous week [42]

Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company reported a revenue of 19.514 billion yuan for H1 2025, a year-on-year decrease of 4.63%, primarily due to the impact of drug procurement policies. However, revenue from innovative drugs exceeded 4.3 billion yuan, showing a year-on-year growth of 14.26% [1] - The net profit attributable to the parent company reached 1.702 billion yuan, reflecting a significant year-on-year increase of 38.96%, driven by the sale of remaining equity in Harmony Family and other non-core asset gains [1] - The company has completed two license-out transactions in 2025, indicating a faster-than-expected progress in its innovative drug internationalization efforts [2] - A long-term incentive mechanism has been established, with targets set for net profit and innovative drug revenue, aiming for a compound annual growth rate (CAGR) of approximately 20% from 2025 to 2027 [3] - The subsidiary, Fuhong Hanlin, is making significant progress in clinical trials, which is expected to further enhance the company's performance [4] Financial Forecasts - The revenue forecasts for 2025-2027 have been adjusted to 41.274 billion yuan, 42.496 billion yuan, and 47.572 billion yuan, respectively, while the net profit forecasts have been raised to 3.399 billion yuan, 3.995 billion yuan, and 4.770 billion yuan [5] - The company aims for net profit targets of 3.32 billion yuan, 3.96 billion yuan, and 4.77 billion yuan for 2025-2027, with innovative drug revenue targets of 9.36 billion yuan, 11.23 billion yuan, and 13.48 billion yuan for the same period [3][5]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [2] Core Insights - The biotech sector in China is experiencing stable revenue growth, with a significant reduction in net losses. In the first half of 2025, 32 Chinese biotech companies achieved revenue of 46.356 billion yuan, a year-on-year increase of 17.97%. Leading biotech firms have diversified product lines and international expansion, while some smaller companies are rapidly growing due to their core products [6][16] - There is a notable trend of Chinese innovative drug assets entering global markets, with the total amount of business development (BD) transactions reaching new records. The upfront payments and total transaction amounts for Chinese innovative drug assets have surged from 8.7/99.4 billion USD in 2020 to 49.4/561.2 billion USD in 2024. In the first half of 2025, the total transaction amount reached 63.55 billion USD, surpassing the total for 2024 and accounting for approximately 40% of global license-out transactions [7][24] - The report suggests focusing on investment opportunities in seven major innovative drug sectors over the next 6-12 months, including next-generation immuno-oncology, weight loss, and small nucleic acids, which are expected to see significant developments [9] Summary by Sections Biotech Revenue and Profitability - In the first half of 2025, the net loss of Chinese biotech companies narrowed significantly, with a total net loss of 1.755 billion yuan, a 50.34% reduction compared to the first half of 2024. Notably, companies like BeiGene turned a profit with a net income of 450 million yuan, marking its first profitable period [18][20] International Expansion of Chinese Innovative Drugs - The total amount of transactions involving multinational corporations (MNCs) purchasing Chinese assets has approached 100 billion USD from 2020 to the first half of 2025, with approximately 11 billion USD in upfront payments. Major companies like BMS, AZ, Merck, and Novartis have been particularly active in acquiring Chinese assets [8][27] Investment Recommendations - Recommended stocks include major pharmaceutical and biotech companies such as Hengrui Medicine, Innovent Biologics, and others across various sectors including traditional Chinese medicine, raw materials, medical devices, and healthcare services [10]